Health
Biotech Firms Lobby Against Medicare Price-Cut Programs
A coalition of biotech firms is lobbying to exclude orphan drugs from new federal programs aimed at reducing Medicare drug costs. The move could impact patient access and pricing policies.
Coverage timeline — 4 articles
STAT News
A coalition of biotech firms is lobbying to exclude orphan drugs from new federal pilot programs aimed at lowering Medicare drug costs.
2026-07-21 08:30 UTC
STAT News
“Post-pandemic polarization threatens to lock our memories into attractive, untrue conclusions that will leave us unprotected next time,” write Marc Lipsitch and Sara Cody.
2026-07-21 08:30 UTC
STAT News
The proposed rule could “weaken the NIH’s benign influence over research risks,” writes Doni Bloomfield.
2026-07-21 08:30 UTC
STAT News
THC drinks, which have exploded in popularity in recent years, are sold in retail stores beside sodas, iced tea, and even chocolate milk, often in violation of state laws.
2026-07-21 08:30 UTC